Lirentelimab

Lirentelimab is an experimental drug developed by Medicenna Therapeutics for the treatment of glioblastoma, a type of brain cancer. It is a superkine version of interleukin-2 (IL-2), a protein that regulates the activities of white blood cells (WBCs) that are responsible for immunity. Lirentelimab is designed to selectively bind to the IL-2 receptor on immune cells, thereby stimulating the immune system to attack cancer cells.

Development and Clinical Trials

Lirentelimab, also known as MDNA55, has been studied in multiple clinical trials. In a Phase 2b clinical trial, the drug showed a significant improvement in survival rates for patients with recurrent glioblastoma, compared to historical control data. The drug has received Orphan Drug designation from the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of glioblastoma.

Mechanism of Action

Lirentelimab works by binding to the IL-2 receptor on immune cells, specifically the subunit CD122, which is overexpressed on immune cells in the tumor microenvironment. This binding stimulates the immune cells to attack the cancer cells, while leaving healthy cells unharmed.

Potential Side Effects

As with any drug, lirentelimab may cause side effects. In clinical trials, the most common side effects were fatigue, nausea, and fever. However, these side effects were generally manageable and did not lead to discontinuation of treatment.

Future Directions

Medicenna Therapeutics is currently planning additional clinical trials to further evaluate the safety and efficacy of lirentelimab in patients with glioblastoma and other types of cancer.